Acceleron Pharma, Inc. (XLRN)
Stock Price:
$116.99 USD
3.24 (2.85%)
Updated November 27, 12:32 PM EST - Market open
Key Info
| Market Cap |
7.05B |
| Revenue (ttm) |
106.00M |
| Net Income (ttm) |
-132.21M |
| Shares Out |
60.25M |
| EPS (ttm) |
-2.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$116.99 |
| Previous Close |
$113.75 |
| Change ($) |
3.24 |
| Change (%) |
2.85% |
| Day's Open |
114.47 |
| Day's Range |
113.79 - 117.75 |
| Day's Volume |
192,173 |
| 52-Week Range |
46.00 - 124.01 |
More Stats
| Market Cap |
7.05B |
| Enterprise Value |
6.19B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
60.25M |
| Float |
52.51M |
| EPS (basic) |
-2.39 |
| EPS (diluted) |
-2.40 |
| FCF / Share |
-1.89 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.60M |
| Short Ratio |
12.15 |
| Short % of Float |
6.85% |
| Beta |
0.52 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
66.50 |
| PB Ratio |
7.64 |
| Revenue |
106.00M |
| Operating Income |
-135.29M |
| Net Income |
-132.21M |
| Free Cash Flow |
-112.87M |
| Net Cash |
860.51M |
| Net Cash / Share |
14.28 |
| Gross Margin |
-75.44% |
| Operating Margin |
-127.64% |
| Profit Margin |
-124.70% |
| FCF Margin |
-106.49% |
| ROA |
-11.53% |
| ROE |
-19.44% |
| ROIC |
-63.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (13)
| Buy |
11 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$131.77*
(12.63% upside)
Low
100
Current: $116.99
High
155
Target: 131.77
*Average 12-month price target from 13 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 73.99 | 13.99 | 13.48 | 27.77 | 18.10 | 14.63 | 57.23 | 15.25 | 80.91 |
| Revenue Growth | 428.86% | 3.78% | -51.46% | 53.46% | 23.68% | -74.43% | 275.18% | -81.15% | - |
| Gross Profit | 73.99 | 13.99 | 13.48 | 27.77 | 18.10 | 14.63 | 57.23 | 15.25 | 79.41 |
| Operating Income | -136 | -124 | -110 | -66.11 | -60.88 | -55.46 | 6.95 | -28.89 | 38.56 |
| Net Income | -125 | -119 | -108 | -57.01 | -63.89 | -51.26 | -21.90 | -32.58 | 70.42 |
| Shares Outstanding | 52.45 | 45.90 | 40.42 | 37.43 | 33.30 | 31.52 | 9.41 | 2.40 | 2.33 |
| Earnings Per Share | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -4.15 | -24.84 | 0.78 |
| Operating Cash Flow | -93.80 | -94.71 | -76.54 | -44.55 | -44.21 | -53.22 | -19.65 | -38.88 | 9.06 |
| Capital Expenditures | -3.29 | -2.59 | -4.40 | -3.38 | -0.96 | -0.51 | -0.31 | -0.44 | -0.03 |
| Free Cash Flow | -97.09 | -97.30 | -80.94 | -47.93 | -45.17 | -53.73 | -19.96 | -39.33 | 9.03 |
| Cash & Equivalents | 431 | 291 | 278 | 141 | 106 | 177 | 114 | 40.52 | 65.95 |
| Total Debt | 26.38 | - | - | - | - | - | 16.87 | 20.19 | 6.00 |
| Net Cash / Debt | 405 | 291 | 278 | 141 | 106 | 177 | 97.21 | 20.33 | 59.95 |
| Assets | 505 | 315 | 389 | 248 | 146 | 186 | 124 | 49.21 | 73.79 |
| Liabilities | 55.43 | 22.78 | 23.96 | 22.05 | 37.07 | 30.01 | 65.92 | 71.58 | 64.93 |
| Book Value | 449 | 292 | 365 | 226 | 109 | 156 | 57.81 | -291 | -233 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Acceleron Pharma, Inc. |
| Country |
United States |
| Employees |
237 |
| CEO |
Habib J. Dable |
Stock Information
| Ticker Symbol |
XLRN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: XLRN |
| IPO Date |
September 19, 2013 |
Description
Acceleron Pharma, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.